ICCM is trading 11.8% up today at $6.63 following a late-June commercial update highlighting rapid U.S. adoption of its ProSense system and a significant private placement. - The company reported a 70% increase in its active U.S. install base since receiving FDA marketing authorization, driving significant bullish sentiment. - This growth was further bolstered by a $5.5 million private placement with a healthcare-focused institutional investor on June 17, 2026, providing working capital for continued expansion. - The gains come despite broader market weakness, with the move appearing tied to company-specific news and ongoing post-split volatility.